OUR FOCUS
Committed to Successful Outcomes
One of the Healthcare industry’s most active subsectors, Biopharma draws strong corporate and investor interest in the development of novel medicines to treat significant unmet medical needs. Having a reliable, ongoing source of capital is key to funding the lengthy process of bringing therapies to market.
Investors and corporate clients repeatedly turn to Leerink Partners’ experience and expertise to unlock the growth potential of innovative biopharma companies.
Recent transactions
$80 Million
Placement Agent
Private Placement
November 2024
Undisclosed
Financial Advisor
Global License Agreement with Biosion
November 2024
Undisclosed
Exclusive Financial Advisor
AlloVir Merger with Kalaris Therapeutics
November 2024
$200 Million
Joint Bookrunner
Follow-On
November 2024